- Publication in Multiple Sclerosis and Related Disorders.
BRIUMVI showed lower risk of 24-week confirmed disability progression and lower annualized relapse rates over five years versus both comparators in an indirect comparison. Findings are exploratory.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.